Clinical Trials Browser

Lymphoma, T-Cell, Peripheral × Brentuximab Vedotin × 90 days × Clear all

NCT04569032 2026-02-18

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Phase 2 Completed

82 enrolled 13 charts

Lymphoma, T-Cell, Peripheral